Mylan epinephrine estimated allergies

An estimated 1 in 13 children and 1 in 20 adults are affected by food allergies in the U.S.

The Epinephrine Story

Mylan’s commitment to expanding access to medicine extends beyond just offering products. Take potentially life-threatening allergic reactions, or anaphylaxis. These reactions can occur quickly and without warning. The rate of reported severe allergic reactions to food alone has increased by nearly five times over the past decade. Epinephrine is the only first-line treatment for anaphylaxis.

Awareness, Preparedness and Access

Mylan has worked hard to get the word out about the importance of avoiding allergic triggers, being prepared in case anaphylaxis occurs and helping to ensure that effective treatment is at hand when needed.

Learn more about what we have done to improve access through our resources.

1 in 3

patients prescribed epinephrine failed to carry their medication during a reported anaphylactic event.


of life-threatening allergic reactions reported at schools, for example, have occurred in those with no previous diagnosis of a food allergy.

Mylan Pluse Sign

Every 6 minutes food-related anaphylaxis sends someone to the emergency room

Mylan Epinephrine allergicAsset 22x

Up to 43M people may have allergic sensitivities that put them at risk

Mylan epinephrine estimated


In 2012, Mylan launched the EpiPen4Schools program. It provides four FREE epinephrine auto-injectors to qualifying* U.S. public and private kindergarten, elementary, middle and high schools, along with additional training and educational resources.

Mylan epipen4 arrow

Over the past five years:


free epinephrine auto-injectors have been provided


schools nationwide have participated

of schools

Epinephrine auto-injectors provided through the program have been used more than 2,000 times. This reinforces the need for increased access to treatment in schools.

A Deeper Look

An exploratory, cross-sectional, web-based survey of more than 8,000 schools examined the characteristics of anaphylactic events and EpiPen®(epinephrine injection, USP) Auto-Injectors use in U.S. schools participating in EpiPen4Schools during the 2015-2016 school year.

Results showed:
  • In those events when an epinephrine autoinjector was used, 59.7% were treated with an epinephrine auto-injector provided by the EpiPen4Schools program.
  • There were a total of 1,568 anaphylactic events among students, staff and visitors.

Advancing Public Policy

Mylan partnered with advocacy groups and public policy leaders to back legislation that would permit undesignated, or “stock,” epinephrine auto-injectors, not specific to any brand or student, in schools.

8 to 48

In 2010, eight states had legislation that allowed undesignated, or “stock,” epinephrine in schools. 

Today, 48 states have enacted laws or policies allowing it.

We’ve also worked to make undesignated epinephrine auto-injectors available in other public places, such as restaurants, colleges and universities. As a result, stock epinephrine in public places now is permitted in 31 states.

A survey conducted by the U.S. Centers for Disease Control found that in nearly half of peanut and tree nut allergic reactions in restaurants or other foodservice establishments, the food allergic customers had alerted the restaurant to their severe allergy in advance.

Important Safety Information

Use EpiPen® (epinephrine injection, USP) 0.3 mg or EpiPen Jr® (epinephrine injection, USP) 0.15 mg Auto-Injectors right away when you have an allergic emergency (anaphylaxis). Get emergency medical help right away. You may need further medical attention. Only a healthcare professional should give additional doses of epinephrine if you need more than two injections for a single anaphylactic episode. EpiPen® or EpiPen Jr® should only be injected into the middle of your outer thigh (upper leg), through clothing if necessary. Do not inject into your veins, buttocks, fingers, toes, hands or feet. Hold the leg of young children firmly in place before and during injection to prevent injuries. In case of accidental injection, please seek immediate medical treatment.

Rarely, patients who have used EpiPen® or EpiPen Jr® may develop an infection at the injection site within a few days. Some of these infections can be serious. Call your healthcare professional right away if you have any of the following at an injection site: redness that does not go away, swelling, tenderness, or the area feels warm to the touch.

Tell your healthcare professional about all of your medical conditions, especially if you have asthma, a history of depression, thyroid problems, Parkinson’s disease, diabetes, high blood pressure or heart problems, have any other medical conditions, are pregnant or plan to become pregnant, or are breastfeeding or plan to breastfeed. Be sure to also tell your healthcare professional all the medicines you take, especially medicines for asthma. If you have certain medical conditions, or take certain medicines, your condition may get worse or you may have longer lasting side effects when you use EpiPen® or EpiPen Jr®.

Common side effects include fast, irregular or “pounding” heartbeat, sweating, nausea or vomiting, breathing problems, paleness, dizziness, weakness, shakiness, headache, feelings of over excitement, nervousness or anxiety. These side effects usually go away quickly if you lie down and rest. Tell your healthcare professional if you have any side effect that bothers you or that does not go away.


EpiPen® and EpiPen Jr® Auto-Injectors are for the emergency treatment of life-threatening allergic reactions (anaphylaxis) caused by allergens, exercise, or unknown triggers; and for people who are at increased risk for these reactions. EpiPen® and EpiPen Jr® are intended for immediate administration as emergency supportive therapy only. Seek immediate emergency medical help right away.

Please see the full Prescribing Information and Patient Information.

For additional information please contact us at 800-395-3376.

You are encouraged to report negative side effects of prescription drugs to the FDA.

Visit or call 1-800-FDA-1088.